promoter and coding regions. All markers in that study were found to be negative, or at the most weakly positive, in associations with myocardial infarction and hypertension [6] . Given the importance of the promoter region in gene transcription, we explored a common polymorphic marker (C T) at the promoter region of the TGF-β1 gene (k509 bp) in 371 angiographically defined patients for associations with TGF-β1 levels and severity of CAD [6] . The severity of CAD was measured as the number of significantly diseased coronary arteries ( 50 % luminal obstruction demonstrated angiographically). The study was approved by the Ethics Committee of the University of New South Wales. The polymorphic marker was identified using the polymerase chain reaction to amplify the promoter region with the primers described by Cambien et al. [6] . The polymerase chain reaction products (265 bp) were digested with Bsu361 for the detection of the C T change at k509 bp. The rare T allele eliminated the Bsu361 restriction site whereas when the common C allele was cut it resulted in 194-bp and 71-bp fragments after digestion.
The allele frequency for T −&!* was 0n326 in 371 patients and similar to that reported for the French population (0n343) [6] . The genotype distribution was in HardyWeinburg equilibrium and not different between males and females [ χ# l 0n921, degrees of freedom (df) l 2, P l 0n631]. However, there was no significant difference in either active (F l 0n546, P l 0n579) or total (F l 0n66, P l 0n517) TGF-β1 levels among patients with different genotypes using one-way ANOVA analyses. The total TGF-β1 levels for patients with CC, TC and TT genotypes were (meanspS.E.M.) 58n3p2n1 ng\ml (n l 161), 55n0p2n0 ng\ml (n l 167) and 55n9p4n4 ng\ml (n l 35) respectively ; and for active TGF-β1, logarithmically converted because of skewed distribution, they were 3n77p0n16 ng\ml, 3n78p0n16 ng\ml and 3n51p0n35 ng\ml respectively.
There was also a lack of association between the polymorphic marker and the number of significantly diseased vessels in this patient population (χ# l 4n225, df l 8, P l 0n646). The distribution of the rare TT homozygote among patients with 0, 1, 2 and 3 significantly diseased vessels was 7n7%, 8n4 %, 6.4 % and 12n2 % respectively, and the T allele frequencies were 0n336, 0n306, 0n314 and 0n361 respectively. The T −&!* polymorphism was also not associated with the presence of hypertension. The frequencies of TT homozygotes and the T allele in hypertensive patients (9n1 % and 0n313) were not different from those in non-hypertensive patients (8n4 % and 0n344) (χ# l 2n824, df l 2, P l 0n244). In the patients with or without a history of documented myocardial infarction there were also no differences in numbers of TT homozygotes (7n8 % versus 10 %) or the T allele frequencies (0n321 versus 0n340).
In summary, our study showed that the C T −&!* polymorphism was not associated with levels of active or total TGF-β1, or with the severity of CAD, the occurrence of myocardial infarction or hypertension. We
Received 14 August 1998 conclude that the polymorphism is unlikely to be functional or in linkage with other functional changes.
